 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 53885-35-1 |
| Molecular formula(MF) | C14H14ClNS.HCl |
| Molecular Weight(MW): | 300.25 |
| Alias | Ticlopidine HCL |
| In vitro | Water | 4 mg/mL (13.32 mM) |
|---|---|---|
| DMSO | 1 mg/mL (3.33 mM) | |
| Ethanol | 1 mg/mL (3.33 mM) | |
| In vivo |
| Description | Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Ticlopidine HCl is an antiplatelet drug in the thienopyridine family. Ticlopidine HCl inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen. [1] Ticlopidine HCl inhibits platelet aggregation and prostaglandin synthesis from endogenous substrate through activating basal and PGE1-stimulated activity of the cyclase, preventing PGE2-induced depression of the cyclase activity and thus increasing platelet c-AMP level. [2] |
||
| In vivo | Ticlopidine HCl inhibits platelet aggregation with IC50 of ~2 μM in men. [1] Ticlopidine HCl, when orally administered to rats, results in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme. [2] |